Compugen: The program has already discovered four novel splice variant proteins with potentially superior cancer treatments compared with known proteins.
Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN) today unveiled a new program for finding superior variants of known potential cancer drugs and proteins. The potential drugs will apply monoclonal antibody (mAb) therapy, which stimulates the body's immune system to target cells.
Compugen said that its program has already discovered four novel splice variant proteins with potentially superior cancer treatments compared with known proteins. The company has put the new variants into its drug development pipeline program.
Compugen president & CEO Dr. Anat Cohen-Dayag said, “This is an excellent example of how we can utilize our proprietary predictive biology infrastructure on a ‘market-need’ driven basis."
Compugen's share price rose 1.6% in premarket trading on Nasdaq today to $4.86, giving a market cap of $160 million, after rising 2.2% on the TASE to NIS 16.66.
Published by Globes [online], Israel business news - www.globes-online.com - on April 27, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011